Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Magic mushrooms and MDMA may boost empathy, study finds

NCT ID NCT06081179

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether drugs that boost serotonin—like psilocybin (magic mushrooms) and MDMA (ecstasy)—increase prosocial behavior compared to a dopamine-boosting drug (methylphenidate/Ritalin). 122 healthy adults received single doses and completed tasks measuring empathy, moral decisions, and generosity. The goal was to understand the brain chemistry behind social behavior, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Psilocybin, MDMA, and methylphenidate
What this could lead to
If successful, this study could help us understand how serotonin affects social behavior, potentially guiding future treatments for social disorders.
What could go wrong
This is a small, early-phase study in healthy volunteers, not patients. Results may not apply to real-world social behavior or lead to any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

122 people

The number who actually took part.

Started

Oct 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male or female at the age of 18-40 * Willing and capable to give informed consent for study participation as documented by signature (Informed Consent Form) after the nature of the study has been thoroughly explained * Willing to refrain from drinking alcohol the day before testing session, from drinking alcohol and caffeinated drinks at the testing days and from consuming psychoactive substances two weeks before the first investigation visit and for the duration of the study * Willing to abstain from using drugs that may interfere with the effects of the study medications including sleeping aids, cough medications, beta-blocker or other substances with potentially relevant psychoactive and cardiovascular effects. * Able and willing to comply with all study requirements * Good physical health with no unstable medical conditions, as determined by medical history, physical examination, routine blood labs, electrocardiogram, urine analysis, and urine toxicology * Women of childbearing potential (as defined by: 'the age of carrying or giving birth to a child', normally between 14-45 years of age, not in menopause, last menstrual period (LMP) less than 12 months, no removal of ovaries or uterus, no ligature of Fallopian tubes') must be using an effective, established method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices. Note: female participants who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are not considered as being of childbearing potential * Willing not to drive a traffic vehicle or to operate machines within 48h following substance administration * Have a family member or friend who can pick them up after the substance administration sessions (driving is forbidden at drug treatment days) Exclusion Criteria: * Poor knowledge of the German language * Previous significant adverse response to a hallucinogenic drug (incl. psilocybin), MDMA, or methylphenidate * Allergy or hypersensitivity to previous use of MDMA, psilocybin, or methylphenidate * Lifetime history of hallucinogen (incl. psilocybin), MDMA, or methylphenidate use on more than 10 occasions * Personal and family history of major psychiatric disease (e.g., schizophrenia, schizoaffective disorder, psychosis, major depression, bipolar disorder, psychotic disorder, substance addiction/abuse other than caffeine and nicotine) as defined in the DSM-V (1st and 2nd degree relatives) * History of suicidal behavior * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant * Attention-Deficit/Hyperactivity-Disorder (ADHD) * Any current major medical condition (e.g., neurologic, cardiovascular, metabolic, infectious disease) or any unstable illness as determined by medical history or laboratory tests * Uncorrected hypo-or hyperthyroidism * Uncorrected hypo-and hypertension * Epilepsy * Abnormal electrocardiogram * BMI \<17 or \>35 * Personal history of head trauma, brain/cardiac surgery, fainting, or electroconvulsive therapy * Personal and family history of seizure disorder and strokes (1st and 2nd degree relatives) * Participation in another study where pharmaceutical compounds are given within the 30 days preceding and during the present study * Current psychopharmacological treatment or medication that affects brain function * Use of medications that are contraindicated or otherwise interfere with the effects of the study medications (monoamine oxidase inhibitors, antidepressants, sedatives etc.) * Women who are pregnant or breast feeding, or have the intention to become pregnant during the study (for safety reasons, a urine pregnancy test will be done at the screening visit and before the substance administration) * Enrollment of the investigator, his/her family members, employees, and other dependent persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Psychiatrische Universitätsklinik Zürich

    Zurich, Canton of Zurich, 8032, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.